Evidence Limitations: The available evidence on ipamorelin safety is limited, consisting primarily of review articles and two completed Phase 2 clinical trials. Specific safety data from these trials are not provided in the current evidence base.

Known Side Effects

The current evidence does not provide detailed information about specific side effects of ipamorelin. The available studies focus on broader discussions of peptide therapies rather than ipamorelin-specific adverse events. More comprehensive safety data from clinical trials and post-market surveillance would be needed to establish a complete side effect profile.

Clinical Trial Safety

Two completed Phase 2 trials have evaluated ipamorelin safety:

NCT01280344: Evaluated safety for gastrointestinal function recovery
NCT00672074: Assessed safety for post-operative ileus management

However, specific safety outcomes and adverse event data from these trials are not available in the provided evidence.

Drug Interactions

No specific drug interaction data for ipamorelin is available in the current evidence. Given ipamorelin's mechanism as a growth hormone secretagogue, theoretical interactions with medications affecting growth hormone pathways may exist, but this requires further investigation.

Contraindications and Special Populations

The evidence does not provide specific contraindications for ipamorelin use. Clear guidance on populations that should avoid ipamorelin cannot be established based on the available data.

Regulatory and Clinical Context

Multiple reviews note concerns about peptide therapies being used outside of approved clinical contexts, particularly in sports and aesthetic medicine. The available evidence emphasizes the need for proper clinical oversight and regulatory compliance when considering peptide therapies.

Evidence Gaps

Significant limitations exist in the current safety evidence for ipamorelin:

Limited published safety data from completed clinical trials
Lack of long-term safety studies
Insufficient data on special populations (pregnancy, pediatrics, elderly)
No comprehensive adverse event profiles available

Disclaimer: This information is for educational purposes only and should not replace professional medical advice. Healthcare providers should consult current prescribing information and conduct thorough risk-benefit assessments before considering any peptide therapy.

Ipamorelin